Brigimadlin

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameBrigimadlin
Drug Alias NameBI-907828
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 antagonists
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgSino Biopharmaceutical LtdBurning Rock Biotech Ltd +[4] 
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsSolid tumoursGlioblastomaLiposarcoma
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG